Condition: Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma · Sponsor: Polaris Group
Evaluate efficacy and safety of ADI-PEG 20 in patients with high-argininephenotypic and HCC
This description comes directly from the study's public registry record.
Maureen Liu · +886226562727 · mliu@polarispharma.com
Doris Cheng · +886226562727 · dorischeng@polarispharma.com
Always discuss trial participation with your own doctor first.
| Changhua Christian Hospital (CCH) | Changhua, Taiwan | Recruiting |
| Ditmanson Medical Foundation Chiayi Christian Hospital (CYCH) | Chiayi City, Taiwan | Recruiting |
| Chang Gung Medical Foundation-Chia-Yi (CGMF-CY) | Chiayi City, Taiwan | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) | Kaohsiung City, Taiwan | Recruiting |
| Chang Gung Medical Foundation-Kaohsiung(CGMF-KS) | Kaohsiung City, Taiwan | Recruiting |
| Chi Mei Medical Center (CMMC-YK) | Tainan, Taiwan | Recruiting |
| Chi Mei Hospital, Liouying (CMMC-LY) | Tainan, Taiwan | Recruiting |
| Chang Gung Medical Foundation-Linkou (CGMF-LK) | Taoyuan, Taiwan | Recruiting |
| Bach Mai Hospital | Hanoi, Vietnam | Not Yet Recruiting |
| K Hospital | Hà Nội, Vietnam | Not Yet Recruiting |
| Hue Central Hospital | Huế, Vietnam | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05317819